Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study

LESSONS LEARNED. The findings of this prospective, single‐arm, phase II study showed that neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in patients with stage IIIA‐N2 epidermal growth factor receptor mutation‐positive non‐small cell lung cancer (NSCLC). Erloti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Xiong, Liwen, Li, Rong, Sun, Jiayuan, Lou, Yuqing, Zhang, Weiyan, Bai, Hao, Wang, Huiming, Shen, Jie, Jing, Bo, Shi, Chunlei, Zhong, Hua, Gu, Aiqin, Jiang, Liyan, Shi, Jianxing, Fang, Wentao, Zhao, Heng, Zhang, Jie, Wang, Junyuan, Ye, Junyi, Han, Baohui
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2018
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6369937/
https://ncbi.nlm.nih.gov/pubmed/30158288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0120
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky